Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 17 | 13 | +0,26 % | ||
| INSMED | 12 | 7 | -17,06 % | ||
| AVADEL PHARMACEUTICALS | 10 | 6 | 0,00 % | ||
| MODERNA | 8 | 16 | +1,54 % | ||
| GILEAD SCIENCES | 4 | 5 | +0,50 % | ||
| ANAVEX LIFE SCIENCES | 4 | - | +2,30 % | ||
| PYXIS ONCOLOGY | 4 | - | 0,00 % | ||
| INCYTE | 3 | 25 | +0,12 % | ||
| BEONE MEDICINES LTD ADR | 3 | 10 | +1,54 % | ||
| ABCELLERA BIOLOGICS | 3 | 1 | +3,82 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:30 | Gilead Sciences CDR (CAD Hedged): Gilead Sciences CDR to be delisted from Cboe | 9 | Stockwatch | ||
| Do | Phibro Animal Health announces CEO transition effective July 2026 | 2 | Investing.com | ||
| Do | CEPI steps in to fund Moderna's pandemic flu jab | 7 | pharmaphorum | ||
| Do | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Do | Phibro Animal Health announces CEO transition | 1 | Seeking Alpha | ||
| Do | Biogen stock rated Outperform by RBC Capital with $210 price target | 4 | Investing.com | ||
| Do | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Do | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors | 2 | GlobeNewswire (USA) | ||
| Do | RBC Capital stuft Biogen mit "Outperform" ein und setzt Kursziel auf 210 US-Dollar | 3 | Investing.com Deutsch | ||
| Do | Galapagos NV: Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus | 231 | GlobeNewswire (Europe) | GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo
In... ► Artikel lesen | |
| Do | BeOne Medicines Ltd.: BeOne Medicines erhält von der US-amerikanischen FDA Fast-Track-Status für BGB-B2033 zur Behandlung von Leberzellkarzinomen | 159 | Business Wire | BGB-B2033 ist ein bispezifischer Antikörper, der gegen GPC3 und 4-1BB gerichtet ist, zwei wichtige Zielmoleküle bei der häufigsten Form von Leberkrebs Die Fast-Track-Zulassung der FDA spiegelt... ► Artikel lesen | |
| Do | RBC senkt Kursziel für Pyxis Oncology: Aktie unter Druck nach komplexen Studiendaten | - | Investing.com Deutsch | ||
| Do | Moderna gets funding for H5 pandemic influenza vaccine | 7 | BioPharma Dive | ||
| Do | GALAPAGOS NV - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | OCULAR THERAPEUTIX, INC - 8-K, Current Report | - | SEC Filings | ||
| Do | Pyxis Oncology stock falls as RBC cuts price target on complex trial data | 2 | Investing.com | ||
| Do | PHIBRO ANIMAL HEALTH CORP - 8-K, Current Report | - | SEC Filings | ||
| Do | BioNTech SE - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| Do | Cartesian Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Do | LIGAND PHARMACEUTICALS INC - 8-K, Current Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .